Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 52

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 52
---
5. This is Family 8. Patents granted from this family will expire September 15, 2035 based on a normal 20 year term. In the United States, a granted patent covering TDO candidate peptides and methods of treatment using the same will expire March 1, 2036 due to a patent term adjustment of 168 days. A separate granted patent in the United States covers nucleic acids encoding the TDO candidate peptides and will expire February 21, 2037 due to a patent term adjustment of 525 days. The family includes granted patents in Europe, China, Japan, Australia, Canada, Israel, New Zealand and South Africa. A pending application in Europe covering nucleic acids encoding TDO candidate peptides, has received a notice of allowance. Family 15 listed above is also relevant;  

•PD-L2: We own one patent family based on a PCT application filed October 13, 2017. This is Family 9. Patents granted from this family will expire October 13, 2037 based on a normal 20 year term. The family includes granted patents in the United States and Japan. The family also includes pending applications in the United States, China, Europe, and Hong Kong. Claims are directed to target candidates, and uses thereof.  Family 15 listed above is also relevant;  

•CCL22: We own one patent family based on a PCT application filed September 16, 2016. This is Family 10. Patents granted from this family will expire September 16, 2036 based on a normal 20 year term. The family includes granted patents in the United States, China, Japan, Israel, New Zealand and Australia. The family also includes pending applications in the United States, China, Europe, Hong Kong, and South Africa. Claims are directed to target candidates, and uses thereof.  Grant is underway in Canada. Family 15 listed above is also relevant; 

•Arginase 2: We own three patent families relevant to this target. The first is Family 6 as listed under IO112 (Arginase 1) above. The second is Family 11, based on a PCT application filed November 14, 2019. Patents granted from this family will expire November 14, 2039 based on a normal 20 year term. Family 11 includes pending applications in the United States, China, Europe, Australia, Canada, Israel, and Republic of Korea.  Claims